WO2002072623A1 - Genes and proteins, and their use - Google Patents
Genes and proteins, and their use Download PDFInfo
- Publication number
- WO2002072623A1 WO2002072623A1 PCT/GB2002/001089 GB0201089W WO02072623A1 WO 2002072623 A1 WO2002072623 A1 WO 2002072623A1 GB 0201089 W GB0201089 W GB 0201089W WO 02072623 A1 WO02072623 A1 WO 02072623A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- infection
- peptide
- gene
- gbs
- sequence
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 48
- 102000004169 proteins and genes Human genes 0.000 title abstract description 18
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims abstract description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 31
- 239000012634 fragment Substances 0.000 claims description 20
- 229960005486 vaccine Drugs 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000035357 Focal Infection Diseases 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 208000019206 urinary tract infection Diseases 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000001018 virulence Effects 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010061372 Streptococcal infection Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract description 3
- 238000011203 antimicrobial therapy Methods 0.000 abstract description 2
- 102000018697 Membrane Proteins Human genes 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 11
- 101150009573 phoA gene Proteins 0.000 description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010053555 Arthritis bacterial Diseases 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 208000004575 Infectious Arthritis Diseases 0.000 description 2
- 206010061308 Neonatal infection Diseases 0.000 description 2
- 108010053775 Nisin Proteins 0.000 description 2
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102400000368 Surface protein Human genes 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000004309 nisin Substances 0.000 description 2
- 235000010297 nisin Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 201000001223 septic arthritis Diseases 0.000 description 2
- 229960000268 spectinomycin Drugs 0.000 description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101100455969 Bacillus subtilis (strain 168) mdxK gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101100053968 Escherichia coli (strain K12) znuC gene Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101100173396 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) fbpC1 gene Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 241001625930 Luria Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000194021 Streptococcus suis Species 0.000 description 1
- 108010023191 Streptomycin 3''-adenylyltransferase Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 239000001055 blue pigment Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 101150020570 fbpC gene Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 101150003248 malK gene Proteins 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 101150034875 phoA2 gene Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 101150016899 potA gene Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- This invention relates to the identification of a bacterial gene and protein, and its use. More particularly, it relates to its use in therapy, for immunisation and in screening for drugs .
- Background to the Invention
- GBS Group B Streptococcus
- Streptococcus agalactiae is the causative agent of various conditions.
- GBS causes: Early onset neonatal infection .
- This infection usually begins in utero and causes severe septicaemia and pneumonia in infants, which is lethal if untreated and even with treatment is associated with a 10-20% mortality rate. Late onset neonatal infection .
- This infection occurs in the period shortly after birth until about 3 months of age. It causes a septicaemia, which is complicated by meningitis in 90% of cases. Other focal infections also occur including osteomyelitis, septic arthritis, abscesses and endopthalmitis . Adul t infections .
- Urinary tract infections GBS is a cause of urinary tract infections and in pregnancy accounts for about 10% of all infections.
- Veterinary infections .
- GBS causes chronic mastitis in cows. This, in turn, leads to reduced milk production and is therefore of considerable economic importance.
- GBS infections can be treated with antibiotics.
- immunisation is preferable. It is therefore desirable to develop an immunogen that could be used in a therapeutically-effective vaccine .
- the present invention is based on the identification of a gene in GBS, and also related organisms, the product of which may be localised on the outer surface of the organism and therefore may be used as a target for immuno- therapy.
- a peptide is encoded by a gene identified herein as pho2-2, obtainable from Group B Streptococcus, or a homologue or functional fragment thereof. Such a peptide is suitable for therapeutic use, e.g. when isolated.
- a functional fragment is used herein to define a part of the gene or peptide which retains the activity of the whole gene or peptide.
- a functional fragment of the peptide may be used as an antigenic determinant, useful in a vaccine or in the production of antibodies .
- a gene fragment may be used to encode the active peptide.
- the gene fragment may have utility in gene therapy, targetting the -wild-type gene in vivo to exert a therapeutic effect.
- a peptide according to the present invention may comprise the amino acid sequence identified herein as SEQ ID NO. 2, or a functional fragment thereof.
- the peptide of the present invention may be a suitable candidate for the production of therapeutically-effective vaccines against GBS.
- the term "therapeutically-effective" is intended to include the prophylactic effect of vaccines.
- a vaccine may comprise a peptide according to the invention, or the means for its expression, for the treatment of infection.
- the vaccine may be administered to females prior to or during pregnancy to protect mother and neonate against infection by GBS.
- the peptide or gene may be used for screening potential antimicrobial drugs or for the detection of virulence.
- a further aspect of this invention is the use of any of the products identified herein, for the treatment or prevention of a condition associated with infection by a Group B Streptococcal strain.
- the protein has been described for use in the treatment of patients, veterinary uses of the products of the invention are also considered to be within the scope of the present invention.
- the peptide or the vaccines may be used in the treatment of chronic mastitis, especially in cows. Description of the Drawings The invention is described with reference to the accompanying drawing where :
- Figure 1 is a graphic illustration of the average level of protection offered by anti-pho2-2 anti-sera against a challenge dose of GBS. Description of the Invention
- the present invention is described with reference to Group B Streptococcal strain M732.
- GBS strains and many other bacterial strains are likely to include related peptides or proteins having amino acid sequence homology with the peptide of M732.
- Organisms likely to contain the peptide include, but are not limited to, S. pneumoniae, S. pyogenes, S. suis, S. miller i , Group C and Group G Streptococci and Enterococci . Vaccines to each of these may be developed in the same way as described for GBS.
- the peptides that may be useful for the production of vaccines have greater than 40% sequence similarity with the peptide identified herein. More preferably, the peptides have greater than 60% sequence similarity. Most preferably, the peptides have greater than 80% sequence similarity, e.g. 95% similarity.
- related polynucleotides that may be useful in the various aspects of the invention may have greater than 40% identity with the sequence identified herein. More preferably, the polynucleotide sequences have greater than 60% sequence identity. Most preferably, the polynucleotide sequences have greater than 80% sequence identity, e.g. 95% identity.
- similarity refers to a sequence comparison based on identical matches between correspondingly identical positions in the sequences being compared.
- similarity refers to a comparison between amino acid sequences, and takes into account not only identical amino acids in corresponding positions, but also functionally similar amino acids in corresponding positions. Thus similarity between polypeptide sequences indicates functional similarity, in addition to sequence similarity.
- Levels of identity between gene sequences and levels of identity or similarity between amino acid sequences can be calculated using known methods.
- publicly available computer based methods for determining identity and similarity include the BLASTP, BLASTN and FASTA (Atschul et al . , J. Molec. Biol . , 1990; 215:403-410), the BLASTX program available from NCBI , and the Gap program from Genetics Computer Group, Madison WI .
- sequence homologies may be established by searching in existing databases, e.g. EMBL or Genbank.
- a fragment of the gene sequence disclosed herein may be used to prepare a vaccine product, or as a probe in a diagnostic method, or to identify homologues in other microorganisms.
- the fragment will be at least 20 nucleic acids, more preferably at least 30 nucleic acids, and most preferably at least 70 nucleic acids.
- hybridisation under stringent conditions means that a positive hybridisation signal is still observed after washing for 1 hour with 1 x SSC buffer and 0.1% SDS at 55°C, preferably at 62°C and most preferably at 68°C.
- Peptides or proteins according to the invention may be purified and isolated by methods known in the art. In particular, having identified the gene sequence, it will be possible to use recombinant techniques to express the genes in a suitable host. Active fragments and homologues can be identified and may be useful in therapy. For example, the peptide or its active fragments may be used as antigenic determinants in a vaccine, to elicit an immune response. They may also be used in the preparation of antibodies, for passive immunisation, or diagnostic applications. Peptide fragments may be used to identify those parts of the protein that have the most favourable antigenic epitopes. The fragments can be generated by methods known to those skilled in the art. For example, partial digests of the complete protein can be made and tested.
- synthetic peptide fragments can be made and tested. The fragments may be tested to establish which fragments elicit the strongest immune response .
- a therapeutic antibody of the invention will have affinity for the protein (or peptide) of the invention and preferably should not cross-react with unrelated proteins or proteins in the patient.
- Suitable antibodies which may be active against the peptide of the invention include monoclonal antibodies, or fragments thereof, including single chain fv fragments.
- Vaccine compositions can be formulated with suitable carriers or adjuvants, e.g. alum, as necessary or desired, and used in therapy, to provide effective immunisation against Group B Streptococci or other microorganisms that contain related proteins.
- suitable carriers or adjuvants e.g. alum
- the preparation of vaccine formulations will be apparent to the skilled person.
- a suitable amount of an active component of the invention can be selected, for therapeutic use, as can suitable carriers or excipients, and routes of administration. These factors will be chosen or determined according to known criteria such as the nature/severity of the condition to be treated, the type or health of the subject etc.
- the products of the invention may also be used in assays to screen potential antimicrobial drugs.
- the protein of the invention may be used as a target for antimicrobial therapy, to localise a drug to the infecting microbe.
- a partial gene library of GBS (strain M732) chromosomal DNA was prepared using the plasmid vectors pFW-phoAl, pFW- phoA2 and pFW-phoA3 (Podbielski, A. et al . 1996. Gene 177:137-147). These plasmids possess a constitutive spectinomycin adenyltransferase antibiotic resistance marker, which confers a high level of spectinomycin resistance and is therefore easily selected. Furthermore, these vectors contain a truncated (leaderless) Escherichia coli phoA gene for alkaline phosphatase.
- the three vectors differ only with respect to the reading frame in which the leaderless phoA gene exists, as compared to an upstream in- frame BamHI restriction enzyme site. Because this truncated E. coli phoA gene lacks the appropriate leader sequence for export of this enzyme across the bacterial membrane, extracellular alkaline phosphatase activity is absent when these plasmids are propagated in an E. coli phoA mutant (e.g. strain DH5 ) .
- the chromogenic alkaline phosphatase substrate, XP (5-bromo-4-chloro-3-indolyl-phosphate) does not enter intact bacterial cells and therefore only exported or surface associated alkaline phosphatase activity can be detected. When exported or surface associated alkaline phosphatase activity is present, the chromogenic XP substrate is cleaved to yield a blue pigment and the corresponding bacterial colonies can be identified by their blue colour.
- Plasmid DNA was digested to completion with BamHI and dephosphorylated using shrimp alkaline phosphatase.
- GBS genomic DNA was partially digested with Sau3AI , size fractionated on a sucrose gradient and fragments ⁇ lkb in size were ligated into the prepared pFW-p oA vectors.
- E. coli strain DH5 was chosen as the cloning host since it lacks a functional phoA gene.
- Recombinant plasmids were selected on Luria agar containing 100 ⁇ g/ml of spectinomycin and 40 ⁇ g/ml of the chromogenic XP substrate.
- a comparison of the amino acid sequence of pho2-2 was performed. Homologues to the GBS pho2-2 gene product can be identified in Enterococcus faecalis, Escherichia coli ( alK and afuC) , Bacillus subtilis (glnO) , Haemophilus influenzae (yebM and potA) , Streptococcus pyogenes, Streptococcus pneumoniae and Salmonella typhi urium (malK) . The E. faecalis , S . pyogenes and S . pneumoniae homologues were identified from genome sequence data and no annotations were available as to the identity of the gene or gene products.
- homologues represented ATP-binding transport proteins that are part of ABC type transporters.
- Many of the components of ABC type transporters are membrane or cell surface associated, as these systems are involved in the transport of macromolecules from the extracellular environment to the intracellular compartment.
- oligonucleotide primers were designed for genomic DNA sequencing. These primers were designed so as to sequence in an "outward 1 direction from the obtained sequence. Once read, the sequence obtained was checked to see if the 5' and 3' termini of the gene had been reached. The presence of these features was identified by checking against homologous sequences, and for the 5' end the presence of an AUG start codon (or accepted equivalent) preceded by a Shine-Dalgarno consensus sequence, and for the 3 1 end, the presence of a translation termination (Stop) codon.
- AUG start codon or accepted equivalent
- primers were designed for amplification of full-length product.
- Primers used included restriction enzyme recognition sites (Ncol at the 5 ' end and EcoO109I at the 3 1 end) to allow subsequent cloning of the product into the Lactococcal expression system used.
- PCR was carried out using the primers, and the products cloned into a pCR 2.1 cloning vector (Invitrogen) .
- the vector into which this fragment was inserted was a modified version of pNZ8048 (Kuipers, O. P. et al . (1998) J. Biotech 64: 15-21).
- This vector harbouring a lactococcal origin of replication, a chloramphenicol resistance marker, an inducible nisin promoter and a multicloning site was altered by the replacement of the multicloning site with two 10X His tags, flanked on the 5- most end with an Ncol site, split in the middle with a multicloning site (including an EcoO109I site) , and a stop (termination) codon at the 3' end of the His tags.
- the gene of interest was inserted so that a 10X His tag was in the 3' position relative to the coding region.
- a 400 ml liquid culture was set up and translation of the protein was induced by the addition of nisin to the culture. After a 2 hour incubation, the cells were harvested and lysed by bead beating. The resultant lysate was cleared by centrifugation, then passed over a metal affinity (Talon, Clonetech) column. The column was washed repeatedly before bound proteins were eluted with Imidazole.
- the recombinant protein obtained was then used to immunise New Zealand white rabbits, with pre-immune sera being harvested prior to immunisation. Following a boost, the rabbits were sacrificed and sera collected. This sera was used in Western blots, ELISA and animal protection models .
- Anti-sera against the pho2-2 outer surface protein and a further protein (pho3-9) identified in the same screen were raised in rabbits and the IgG from each anti-sera was purified using Protein A column chromatography. Newborn pups from time-mated Sprague Dawley rats were " "immunised' with 50 ⁇ l of the purified IgG intraperitoneally and returned to different mothers for at least 5 hours before they were challenged with the GBS.
- the A909 strain of GBS was used as the challenge. The strain was streaked on to a blood agar plate, and allowed to grow over the weekend at room temperature. A single colony of GBS was used to produce the inoculum in THB. Following overnight growth, the GBS bacteria were centrifuged, and an appropriate volume of PBS added to produce a final dilution of 1 x 10 5 CFU/ml GBS (5 x 10 4 GBS/ 50 ⁇ l) . The innoculum was kept on ice until use in the challenge assay in the rat pups.
- the GBS was administered subcutaneously to each rat and the time of challenge recorded. All pups were monitored for approximately 63 hours after the GBS challenge.
- Table A shows the percentage of pups that survived 63 hours after challenge with GBS. This data has been represented in a graph in figure 1.
- the pho2-2 protein offered significant protection against GBS infection compared to the PBS control and to the other outer surface protein pho3-9.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02704946A EP1366068A1 (en) | 2001-03-09 | 2002-03-11 | Poynucleotide and polypeptide from group b streptococcus and use thereof for the preparation of a vaccine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0105922.9A GB0105922D0 (en) | 2001-03-09 | 2001-03-09 | Genes and proteins, and their use |
GB0105922.9 | 2001-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002072623A1 true WO2002072623A1 (en) | 2002-09-19 |
Family
ID=9910382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2002/001089 WO2002072623A1 (en) | 2001-03-09 | 2002-03-11 | Genes and proteins, and their use |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1366068A1 (en) |
GB (1) | GB0105922D0 (en) |
WO (1) | WO2002072623A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008152448A2 (en) * | 2006-12-21 | 2008-12-18 | Emergent Product Development Uk Limited | Streptococcus proteins, and their use in vaccination |
US7592011B2 (en) | 1998-12-22 | 2009-09-22 | Emergent Product Development Uk Limited | Genes and proteins, and their use |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999042588A2 (en) * | 1998-02-20 | 1999-08-26 | Biochem Pharma Inc. | Group b streptococcus antigens |
US6015889A (en) * | 1993-03-19 | 2000-01-18 | Gunnar Lindahl | Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition |
WO2000006736A2 (en) * | 1998-07-27 | 2000-02-10 | Microbial Technics Limited | Nucleic acids and proteins from group b streptococcus |
WO2000037646A2 (en) * | 1998-12-22 | 2000-06-29 | Microscience Limited | Group b streptococcus proteins, and their use |
-
2001
- 2001-03-09 GB GBGB0105922.9A patent/GB0105922D0/en not_active Ceased
-
2002
- 2002-03-11 EP EP02704946A patent/EP1366068A1/en not_active Withdrawn
- 2002-03-11 WO PCT/GB2002/001089 patent/WO2002072623A1/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6015889A (en) * | 1993-03-19 | 2000-01-18 | Gunnar Lindahl | Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition |
WO1999042588A2 (en) * | 1998-02-20 | 1999-08-26 | Biochem Pharma Inc. | Group b streptococcus antigens |
WO2000006736A2 (en) * | 1998-07-27 | 2000-02-10 | Microbial Technics Limited | Nucleic acids and proteins from group b streptococcus |
WO2000037646A2 (en) * | 1998-12-22 | 2000-06-29 | Microscience Limited | Group b streptococcus proteins, and their use |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7592011B2 (en) | 1998-12-22 | 2009-09-22 | Emergent Product Development Uk Limited | Genes and proteins, and their use |
WO2008152448A2 (en) * | 2006-12-21 | 2008-12-18 | Emergent Product Development Uk Limited | Streptococcus proteins, and their use in vaccination |
WO2008152448A3 (en) * | 2006-12-21 | 2009-05-22 | Emergent Product Dev Uk Ltd | Streptococcus proteins, and their use in vaccination |
Also Published As
Publication number | Publication date |
---|---|
EP1366068A1 (en) | 2003-12-03 |
GB0105922D0 (en) | 2001-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090274717A1 (en) | Genes and proteins, and their use | |
US20080226641A1 (en) | Outer surface proteins, their genes, and their use | |
US7592011B2 (en) | Genes and proteins, and their use | |
EP1366068A1 (en) | Poynucleotide and polypeptide from group b streptococcus and use thereof for the preparation of a vaccine | |
JP2001504335A (en) | Lactoferrin-binding protein of Streptococcus uberis | |
ZA200104818B (en) | Genes and proteins, and their use. | |
AU2005203729B2 (en) | Outer surface proteins, their genes, and their use | |
AU2004201404B2 (en) | Genes and proteins, and their use | |
NZ543923A (en) | Pho3-18 for a theraputic use, particulary in bacterial infection. | |
ZA200104819B (en) | Outer surface proteins, their genes, and their use. | |
PL195869B1 (en) | Outer surface proteins, their genes, and their use | |
NZ533932A (en) | MS11 gene product encoding for a phosphoglycerate kinase, and a purine nucleoside phosphatase and glucose-6-phosphate isomerase proteins from Group B streprococcus and their use in treating bacterial infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002704946 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002704946 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002704946 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |